Anaplastic thyroid cancer: How far can we go?

Area of Science:

• Oncology
• Endocrinology

Background:

• Thyroid cancer comprises 2% of global diagnoses, categorized into differentiated and undifferentiated types.
• Differentiated thyroid carcinomas generally have good prognoses with standard therapies like surgery, radioactive iodine, and hormone treatment.
• Anaplastic thyroid carcinoma (ATC), an aggressive undifferentiated subtype, is resistant to conventional treatments and often diagnosed at advanced stages.

Purpose of the Study:

• To review current treatment approaches for thyroid carcinomas, with a specific focus on anaplastic thyroid carcinoma.
• To explore the challenges and obstacles associated with treating anaplastic thyroid carcinoma due to its undifferentiated nature.
• To overview novel therapeutic strategies and ongoing clinical trials for anaplastic thyroid carcinoma.

Main Methods:

• Literature review focusing on thyroid cancer classification and treatment modalities.
• Analysis of current therapeutic options for differentiated and undifferentiated thyroid carcinomas.
• Examination of emerging treatments and clinical trial data for anaplastic thyroid carcinoma.

Main Results:

• Differentiated thyroid carcinomas respond well to established therapies.
• Anaplastic thyroid carcinoma exhibits resistance to radioactive iodine, hormone therapy, and systemic chemotherapy.
• Emerging multi-targeted agents and clinical trials show promising outcomes in survival rates, progression-free survival, and tumor shrinkage for ATC.

Conclusions:

• Anaplastic thyroid carcinoma remains a significant clinical challenge due to its aggressive nature and poor response to conventional treatments.
• Understanding the molecular underpinnings of ATC's undifferentiated phenotype is crucial for developing effective therapies.
• Novel therapeutic strategies and ongoing clinical trials represent a hopeful direction for improving outcomes in anaplastic thyroid carcinoma patients.